MGMT Promoter Methylation Cutoff With Safety Margin for Selecting Glioblastoma Patients Into Trials Omitting Temozolomide. A Pooled Analysis of Four Clinical Trials.
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-18-3181
Full Text
Open PDFAbstract
Available in full text
Date
December 4, 2018
Authors
Publisher
American Association for Cancer Research (AACR)